IRadimed Corporation (IRMD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IRadimed Corporation (IRMD) trades at $99.17 with AI Score 48/100 (Weak). IRADIMED CORPORATION specializes in developing, manufacturing, and distributing MRI-compatible medical devices. Market cap: 2B, Sector: Healthcare.
Last analyzed: Feb 9, 2026IRadimed Corporation (IRMD) Healthcare & Pipeline Overview
IRADIMED CORPORATION is a leader in MRI-compatible medical devices, offering innovative solutions like the MRidium IV infusion pump and patient vital signs monitoring systems, ensuring patient safety and clinical efficiency in MRI environments, and boasting a strong 26.3% profit margin.
Investment Thesis
IRADIMED CORPORATION presents a notable research candidate due to its leadership position in the niche market of MRI-compatible medical devices. The increasing demand for MRI procedures, coupled with the growing awareness of patient safety in MRI environments, drives the need for IRADIMED's specialized products. The company's high gross margin of 77.1% and a profit margin of 26.3% demonstrate strong profitability and efficient operations. The company's dividend yield of 1.23% provides a steady return. Key growth catalysts include expanding the product portfolio with innovative MRI-compatible devices and accessories, penetrating new international markets, and leveraging the company's established sales and distribution network. With a market capitalization of $1.22 billion and a P/E ratio of 57.63, IRADIMED offers a unique blend of growth potential and financial stability in the healthcare sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.22B reflects investor confidence in IRADIMED's market position and growth prospects.
- P/E ratio of 57.63 indicates a premium valuation, reflecting expectations of future earnings growth.
- Profit Margin of 26.3% demonstrates strong profitability and efficient cost management.
- Gross Margin of 77.1% highlights the company's pricing power and value proposition in the specialized MRI-compatible medical device market.
- Dividend Yield of 1.23% provides a consistent return to shareholders, enhancing the investment appeal.
Competitors & Peers
Strengths
- Specialization in MRI-compatible medical devices.
- Strong gross and profit margins.
- Established brand reputation.
- Proprietary technology and intellectual property.
Weaknesses
- Limited product diversification.
- Reliance on a niche market.
- High P/E ratio may indicate overvaluation.
- Relatively small size compared to larger medical device companies.
Catalysts
- Launch of new MRI-compatible medical devices and accessories in Q3 2026.
- Expansion into new international markets, particularly in Asia and Europe.
- Increasing adoption of MRI-guided interventions in hospitals and imaging centers.
- Strategic partnerships with leading healthcare providers and research institutions.
Risks
- Competition from larger medical device companies with greater resources.
- Technological advancements that could render existing products obsolete.
- Changes in regulatory requirements that could increase compliance costs.
- Economic downturns that could reduce healthcare spending and impact sales.
- Dependence on a niche market, making the company vulnerable to changes in MRI technology or clinical practices.
Growth Opportunities
- Expanding the Product Portfolio: IRADIMED has the opportunity to develop and launch new MRI-compatible medical devices and accessories to address unmet clinical needs. This includes exploring innovative solutions for patient monitoring, drug delivery, and surgical procedures within the MRI environment. The market for MRI-compatible devices is estimated to grow significantly over the next five years, driven by the increasing adoption of MRI-guided interventions. By investing in research and development, IRADIMED can capture a larger share of this expanding market and solidify its leadership position.
- Penetrating New International Markets: IRADIMED can expand its geographic reach by entering new international markets with a growing demand for MRI procedures. This includes targeting countries in Asia, Europe, and Latin America, where healthcare infrastructure is developing and access to advanced medical imaging technologies is increasing. By establishing strategic partnerships with local distributors and healthcare providers, IRADIMED can navigate regulatory hurdles and establish a strong presence in these emerging markets. This international expansion will diversify the company's revenue streams and reduce its reliance on the US market.
- Leveraging the Established Sales and Distribution Network: IRADIMED can leverage its existing sales and distribution network to promote and sell its products to a wider customer base. This includes strengthening relationships with hospitals, acute care facilities, and outpatient imaging centers, as well as expanding its reach to new customer segments, such as research institutions and academic medical centers. By providing comprehensive training and support to its sales team, IRADIMED can enhance its ability to educate healthcare providers about the benefits of its MRI-compatible devices and drive sales growth.
- Strategic Acquisitions and Partnerships: IRADIMED can pursue strategic acquisitions and partnerships to expand its product offerings, access new technologies, and enter new markets. This includes targeting companies with complementary product lines or expertise in areas such as medical imaging, patient monitoring, or drug delivery. By integrating these acquisitions and partnerships, IRADIMED can create synergies and enhance its competitive position in the MRI-compatible medical device market. These strategic moves can accelerate the company's growth trajectory and create long-term value for shareholders.
- Increasing Awareness and Education: IRADIMED can invest in marketing and educational initiatives to raise awareness of the importance of MRI-compatible medical devices and the benefits of its products. This includes participating in industry conferences, publishing scientific articles, and conducting webinars and training programs for healthcare providers. By educating the market about the risks associated with using non-compatible devices in MRI environments, IRADIMED can drive demand for its safe and effective solutions and establish itself as a thought leader in the field.
Opportunities
- Expanding product portfolio with new MRI-compatible devices.
- Penetrating new international markets.
- Strategic acquisitions and partnerships.
- Increasing awareness and education about MRI safety.
Threats
- Competition from larger medical device companies.
- Technological advancements that could render existing products obsolete.
- Changes in regulatory requirements.
- Economic downturns that could reduce healthcare spending.
Competitive Advantages
- Specialized Expertise: Deep understanding of MRI compatibility requirements.
- Regulatory Approvals: FDA clearances and other regulatory approvals create barriers to entry.
- Brand Reputation: Established reputation for safety and reliability in MRI environments.
- Customer Relationships: Strong relationships with hospitals and imaging centers.
About IRMD
IRADIMED CORPORATION, founded in 1992 and headquartered in Winter Springs, Florida, is a global leader in the development, manufacture, and distribution of magnetic resonance imaging (MRI) compatible medical devices. The company's core mission is to provide safe and effective solutions for patients undergoing MRI procedures, addressing the critical need for medical devices that can operate safely within the powerful magnetic fields of MRI scanners. IRADIMED's flagship product is the MRidium MRI compatible intravenous (IV) infusion pump system, designed to deliver medication and fluids safely and accurately during MRI scans. This system includes associated disposable IV tubing sets, ensuring a closed and sterile fluid pathway. The company also offers an MRI compatible patient vital signs monitoring system, which allows clinicians to continuously monitor a patient's physiological parameters, such as heart rate, blood pressure, and oxygen saturation, throughout the MRI procedure. Beyond these core products, IRADIMED provides a range of complementary accessories, including non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. These products are sold through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors, targeting hospitals, acute care facilities, and outpatient imaging centers both in the United States and internationally. IRADIMED's commitment to innovation and patient safety has established it as a trusted partner for healthcare providers seeking to enhance the quality and safety of MRI-guided care.
What They Do
- Develops MRI-compatible intravenous (IV) infusion pump systems.
- Manufactures MRI-compatible patient vital signs monitoring systems.
- Offers disposable IV tubing sets for use with its infusion pumps.
- Provides non-magnetic IV poles for MRI environments.
- Supplies wireless remote displays and controls for medical devices.
- Offers side car pump modules and dose error reduction systems.
- Provides SpO2 monitoring solutions with sensors and accessories.
Business Model
- Sells MRI-compatible medical devices and accessories to hospitals and imaging centers.
- Generates revenue from the sale of disposable IV tubing sets.
- Provides maintenance and repair services for its installed base of medical devices.
- Offers training and support services to healthcare providers.
Industry Context
IRADIMED CORPORATION operates within the medical device industry, specifically focusing on MRI-compatible devices. The global medical device market is experiencing steady growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in medical imaging. The demand for MRI procedures is rising, creating a greater need for devices that can safely operate within MRI environments. IRADIMED differentiates itself through its specialization in MRI compatibility, a critical safety requirement. Competitors like AHCO, AXGN, CRON, CTEV, and GDRX operate in the broader medical device market, but do not have the same specialization.
Key Customers
- Hospitals and acute care facilities.
- Outpatient imaging centers.
- Research institutions.
- Academic medical centers.
Financials
Chart & Info
IRadimed Corporation (IRMD) stock price: $99.17 (-0.03, -0.03%)
Latest News
-
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
zacks.com · Mar 23, 2026
-
Iradimed Insider Sold Shares Worth $762,971, According to a Recent SEC Filing
MT Newswires · Mar 18, 2026
-
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
globenewswire.com · Mar 16, 2026
-
Why The IRADIMED (IRMD) Story Is Shifting As Analysts Update Targets And Guidance Arrives
Yahoo! Finance: IRMD News · Mar 13, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IRMD.
Price Targets
Consensus target: $120.00
MoonshotScore
What does this score mean?
The MoonshotScore rates IRMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
Iradimed Insider Sold Shares Worth $762,971, According to a Recent SEC Filing
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
Why The IRADIMED (IRMD) Story Is Shifting As Analysts Update Targets And Guidance Arrives
Common Questions About IRMD (Healthcare)
What does IRadimed Corporation do?
IRADIMED CORPORATION specializes in the development, manufacturing, and distribution of MRI-compatible medical devices. Their primary focus is on creating solutions that ensure patient safety during MRI procedures. The company's flagship products include the MRidium MRI compatible IV infusion pump system and MRI compatible patient vital signs monitoring system. These devices are designed to operate safely and effectively within the strong magnetic fields of MRI scanners, addressing a critical need in the healthcare industry. IRADIMED serves hospitals, acute care facilities, and outpatient imaging centers both in the United States and internationally, providing them with the tools necessary to deliver safe and high-quality MRI-guided care.
Is IRMD stock worth researching?
IRMD stock presents a mixed picture for potential investors. The company's strong gross margin of 77.1% and profit margin of 26.3% indicate efficient operations and pricing power. The dividend yield of 1.23% provides a steady income stream. However, the high P/E ratio of 57.63 suggests that the stock is trading at a premium, reflecting high expectations for future growth. Investors should carefully consider the company's growth prospects, competitive landscape, and potential risks before making an investment decision. The increasing demand for MRI procedures and IRADIMED's leadership in MRI-compatible devices could drive future growth, but competition and technological changes could pose challenges.
What are the main risks for IRMD?
IRADIMED faces several risks, including competition from larger medical device companies with greater resources and broader product portfolios. Technological advancements in medical imaging could render the company's existing products obsolete, requiring significant investments in research and development. Changes in regulatory requirements could increase compliance costs and delay product approvals. Economic downturns could reduce healthcare spending and negatively impact sales. Additionally, the company's reliance on a niche market makes it vulnerable to changes in MRI technology or clinical practices. Investors should carefully assess these risks before investing in IRMD stock.
What are the key factors to evaluate for IRMD?
IRadimed Corporation (IRMD) currently holds an AI score of 48/100, indicating low score. The stock trades at a P/E of 56.3x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $120.00 (+21% from $99.17). Key strength: Specialization in MRI-compatible medical devices. Primary risk to monitor: Competition from larger medical device companies with greater resources. This is not financial advice.
How frequently does IRMD data refresh on this page?
IRMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IRMD's recent stock price performance?
Recent price movement in IRadimed Corporation (IRMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $120.00 implies 21% upside from here. Notable catalyst: Specialization in MRI-compatible medical devices. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IRMD overvalued or undervalued right now?
Determining whether IRadimed Corporation (IRMD) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 56.3. Analysts target $120.00 (+21% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IRMD?
Before investing in IRadimed Corporation (IRMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Future performance is subject to market conditions and company-specific factors.